Pharmacokinetics and organ distribution of intravenous and oral methylene blue

European Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2000, Pages 247-250

  Peter, C ^a   Hongwan, D ^a   Kupfer A ^a   Lauterburg, B H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Distribution; Methylene blue; Pharmacokinetics

Indexed keywords

IFOSFAMIDE; MESNA; METHYLENE BLUE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; TISSUE DISTRIBUTION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; ANIMALS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLENE BLUE; MIDDLE AGED; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0033948654     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000124     Document Type: Article

References (13)

1. 1. Cerny T, Kupfer A (1992) The enigma of ifosfamide encephalopathy (editorial). Ann Oncol 3: 679-681
2. 2. Merimsky O, Inbar M, Reider-Groswasser I, Scharf M, Chaitchik S (1991) Ifosfamide-related acute encephalopathy: clinical and radiological aspects. Eur J Cancer 27: 1188-1189
3. 3. Küpfer A, Aeschlimann C, Wermuth B, Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 343: 763-764
4. 4. Pelgrims J, De Vos F, Van den BJ, Schrijvers D, Prove A, Vermerken JB (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82: 291-294
5. 5. Küpfer A, Aeschlimann C, Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 4: 249-252
6. 6. Zulian GB, Tullen E, Maton B (1995) Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 332: 1239-1240
7. 7. Alonso JL, Nieto Y, Lopez JA, Martin M, Diaz-Rubio E (1996) Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol 7: 643-644
8. 8. Dourthe LM, Coutant G, Desrame J, Merrer J, Daly JP (1999) Ifosfamide-related encephalopathy. Report of two cases. Rev Med Intern 20: 264-266
9. 9. Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42: 428-467
10. 10. Bélaz-David N, Decosterd LA, Appenzeller M, Ruetsch YA, Chiolero R, Buclin T, Biollaz J (1999) Spectrophotometric determination of methylene blue in biological fluids after ion-pair extraction and evidence of its absorption on plastic polymers. Eur J Pharm Sci 5: 335-345
11. 11. Link EM, Costa DC, Lui D, Ell PJ, Blower PJ, Spittle MF (1996) Targeting disseminated melanoma with radiolabelled methylene blue: comparative bio-distribution studies in man and animals. Acta Oncol 35: 331-341
12. 12. DiSanto AR, Wagner JG (1972) Pharmacokinetics of highly ionized drugs. 3. Methylene blue - blood levels in the dog and tissue levels in the rat following intravenous administration. J Pharm Sci 61: 1090-1094
13. 13. DiSanto AR, Wagner JG (1972) Pharmacokinetics of highly ionized drugs. I. Methylene blue - whole blood, urine, and tissue assays. J Pharm Sci 61: 598-602